CR20220141A - Derivados de 2-azaspiro[3,4]octano como agonistas de m4 - Google Patents

Derivados de 2-azaspiro[3,4]octano como agonistas de m4

Info

Publication number
CR20220141A
CR20220141A CR20220141A CR20220141A CR20220141A CR 20220141 A CR20220141 A CR 20220141A CR 20220141 A CR20220141 A CR 20220141A CR 20220141 A CR20220141 A CR 20220141A CR 20220141 A CR20220141 A CR 20220141A
Authority
CR
Costa Rica
Prior art keywords
agonists
azaspiro
octane derivatives
octane
derivatives
Prior art date
Application number
CR20220141A
Other languages
English (en)
Inventor
Amy Calhoun
Xin Chen
Edward Charles Hall
Ming Qian
Kate Yaping Wang
Fan Yang
Keith Jendza
Nancy Labbe-Giguere
Michael David Shultz
Daniel Steven Palacios
Christopher G Thomson
James Neef
Kevin Matthew Gardinier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20220141A publication Critical patent/CR20220141A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

En la presente se proporcionan compuestos de acuerdo con la Fórmula (I) o una sal farmacéuticamente aceptable de los mismos, en donde R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>5</sup>, y R<sup>7</sup> se definen en la presente. También se proporcionan en la presente composiciones farmacéuticas que comprenden un compuesto de Fórmula (I) así como también el uso de dichos compuestos como agonistas del receptor M4.
CR20220141A 2019-10-09 2020-10-07 Derivados de 2-azaspiro[3,4]octano como agonistas de m4 CR20220141A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962912980P 2019-10-09 2019-10-09
PCT/IB2020/059430 WO2021070090A1 (en) 2019-10-09 2020-10-07 2-azaspiro[3.4]octane derivatives as m4 agonists

Publications (1)

Publication Number Publication Date
CR20220141A true CR20220141A (es) 2022-05-03

Family

ID=72944205

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220141A CR20220141A (es) 2019-10-09 2020-10-07 Derivados de 2-azaspiro[3,4]octano como agonistas de m4

Country Status (21)

Country Link
US (2) US11548865B2 (es)
EP (1) EP4041389A1 (es)
JP (1) JP7349570B2 (es)
KR (1) KR20220079921A (es)
CN (1) CN114555592A (es)
AR (1) AR120170A1 (es)
AU (1) AU2020361735B2 (es)
CA (1) CA3156320A1 (es)
CL (1) CL2022000893A1 (es)
CO (1) CO2022004341A2 (es)
CR (1) CR20220141A (es)
CU (1) CU20220023A7 (es)
EC (1) ECSP22027287A (es)
IL (1) IL291316A (es)
JO (1) JOP20220082A1 (es)
MX (1) MX2022004213A (es)
PE (1) PE20221453A1 (es)
TW (1) TW202128649A (es)
UY (1) UY38906A (es)
WO (1) WO2021070090A1 (es)
ZA (1) ZA202202912B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20220082A1 (ar) * 2019-10-09 2023-01-30 Novartis Ag مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
WO2024059249A1 (en) * 2022-09-16 2024-03-21 Cerevel Therapeutics, Llc M4 activators/modulators and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276520A1 (en) 2002-11-13 2006-12-07 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
EP1817032A2 (en) * 2004-11-29 2007-08-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP5420408B2 (ja) 2006-08-25 2014-02-19 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1型のインヒビター
JP2012506883A (ja) 2008-10-29 2012-03-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換されたスピロアミン
BRPI1007350B8 (pt) 2009-01-26 2021-05-25 Israel Institute For Biological Res compostos espiro heterocíclicos bicíclicos
WO2012112743A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
US9226923B2 (en) 2011-07-27 2016-01-05 Nanjing Allgen Pharma Co. Ltd. Spirocyclic molecules as protein kinase inhibitors
CA2881844A1 (en) 2012-09-07 2014-03-13 Zoetis Llc Spirocyclic derivatives as antiparasitic agents
SG11201501620QA (en) 2012-09-18 2015-04-29 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic m1 receptor agonists
SG11201606269WA (en) * 2014-02-06 2016-09-29 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
CA2964103C (en) 2014-10-31 2022-08-30 Indivior Uk Limited Dopamine d3 receptor antagonist compounds
GB201504675D0 (en) * 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513740D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513743D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
EP3805215A1 (en) 2016-06-10 2021-04-14 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
EP3601249A4 (en) 2017-03-24 2020-12-16 Kura Oncology, Inc. METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA
GB201709652D0 (en) 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
HUE061533T2 (hu) 2018-03-23 2023-07-28 Pfizer Piperazin azaspiro származékok
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
JOP20220082A1 (ar) * 2019-10-09 2023-01-30 Novartis Ag مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
US11485742B2 (en) * 2019-10-09 2022-11-01 Novartis Ag 2-azaspiro[3.4]octane derivatives as M4 agonists

Also Published As

Publication number Publication date
ZA202202912B (en) 2023-04-26
AU2020361735A1 (en) 2022-04-21
CN114555592A (zh) 2022-05-27
US11548865B2 (en) 2023-01-10
EP4041389A1 (en) 2022-08-17
MX2022004213A (es) 2022-05-03
CU20220023A7 (es) 2022-11-07
CL2022000893A1 (es) 2023-01-20
JP2022552244A (ja) 2022-12-15
AU2020361735B2 (en) 2024-04-18
PE20221453A1 (es) 2022-09-21
JP7349570B2 (ja) 2023-09-22
CA3156320A1 (en) 2021-04-15
IL291316A (en) 2022-05-01
KR20220079921A (ko) 2022-06-14
WO2021070090A1 (en) 2021-04-15
UY38906A (es) 2021-05-31
CO2022004341A2 (es) 2022-04-29
AR120170A1 (es) 2022-02-02
TW202128649A (zh) 2021-08-01
ECSP22027287A (es) 2022-12-30
US20210107889A1 (en) 2021-04-15
JOP20220082A1 (ar) 2023-01-30
US20230212139A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
CR20220251A (es) Nuevos derivados de metilquinazolinona
MX2021010314A (es) Derivados de tiazol como inhibidores de la secreción de proteínas.
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
WO2019165043A3 (en) Indane-amines as pd-l1 antagonists
ZA202201503B (en) Urea compound for antagonizing lpa1 receptor
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
CR20220141A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
CR20220153A (es) Derivados de 2–azaespiro [3.4] octano como agonistas de m4
WO2019207257A8 (fr) Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
MX2021012105A (es) Compuestos de pirrol.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
CR20210173A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2022004144A (es) Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
WO2020102053A8 (en) Methods of preparing cytotoxic benzodiazepine derivatives
WO2021026479A9 (en) Small molecule inhibitors of s1p2 receptor and uses thereof
WO2020139971A3 (en) Methods for making dimeric naphthalimides and solid state forms of the same
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
BR112022008647A2 (pt) Composto de imidazolidinona, método de preparação do mesmo e uso do mesmo
PH12021550248A1 (en) Borate of azetidine derivative
MX2022002941A (es) Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo.
MX2022004178A (es) Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
MX2021014458A (es) Compuestos triciclicos.
MX2021002260A (es) Compuestos utiles como moduladores de la autofagia mediada por chaperonas.
MX2022006776A (es) Composiciones farmaceuticas oftalmicas.